Evidence map›Paper›PMID 34413137›Full record

ArticleGenes & development2021

Dissecting dual roles of MyoD during lineage conversion to mature myocytes and myogenic stem cells.

Masaki Yagi, Fei Ji, Jocelyn Charlton, Simona Cristea, Kathleen Messemer, Naftali Horwitz, Bruno Di Stefano, Nikolaos Tsopoulidis, Michael S Hoetker, Aaron J Huebner and 10 more

Open access · diamondAbstract read
In one paragraph

Article in Genes & development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Myogenic Potential inACS omega · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Cell identity and 5-hydroxymethylcytosine.Epigenetics & chromatin · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 2 countries.

Masaki YagiDepartment of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Fei JiDepartment of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Jocelyn Charlton *Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts 02138, USA.
Simona Cristea *Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts 02138, USA.
Kathleen MessemerHarvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
Naftali HorwitzHarvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
Bruno Di StefanoDepartment of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Nikolaos TsopoulidisDepartment of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Michael S HoetkerDepartment of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Aaron J HuebnerDepartment of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Ori Bar-NurDepartment of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Albert E AlmadaHarvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
Masakazu YamamotoDepartment of Molecular and Cell Biology, University of Connecticut, Storrs, Connecticut 06269, USA.
Anthony PatelunasDepartment of Molecular and Cell Biology, University of Connecticut, Storrs, Connecticut 06269, USA.
David J GoldhamerDepartment of Molecular and Cell Biology, University of Connecticut, Storrs, Connecticut 06269, USA.
Amy J WagersHarvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
Franziska MichorBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA.
Alexander MeissnerHarvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
Ruslan I SadreyevDepartment of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Konrad HochedlingerDepartment of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Massachusetts General Hospital · USHarvard Stem Cell Institute · USHarvard University · USUniversity of Connecticut · USBroad Institute · USBrigham and Women's Hospital · USJoslin Diabetes Center · US

Funding

ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHRISTOPHER P DUGGAN · 1994 to 2026
$31.6M
Roles of sumoylation and alternative polyadenylation in cellular reprogrammingP01GM099134 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PLATH, KATHRIN · 2011 to 2021
$20.3M
TRAINING IN DIABETES AND METABOLISMT32DK007260 · NIDDK · JOSLIN DIABETES CENTER · PI LAURIE J GOODYEAR · 1986 to 2026
$13.6M
Project 3: Single Cell Measures of Intratumor Diversity for Optimal Breast Cancer TherapyU54CA193461 · NCI · DANA-FARBER CANCER INST · PI POLYAK, KORNELIA · 2015 to 2020
$11.2M
Uncovering molecular effectors of mammalian agingDP1AG063419 · NIA · HARVARD UNIVERSITY · PI WAGERS, AMY JO · 2018 to 2022
$5.9M
Transcription Factor Induced ReprogrammingR01HD058013 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI HOCHEDLINGER, KONRAD · 2010 to 2019
$4.4M
Regulation and Function of Growth Differentiation Factor 11 During Development and AgingR01AG048917 · NIA · HARVARD UNIVERSITY · PI WAGERS, AMY JO · 2016 to 2020
$2.8M
Regulation of Satellite Cell Development, Programming and Differentiation by Myogenic FactorsR01AR076394 · NIAMS · UNIVERSITY OF CONNECTICUT STORRS · PI GOLDHAMER, DAVID J · 2020 to 2024
$2.3M
Investigating the direct reprogramming of fibroblasts into skeletal muscle progenitorsR01AR077695 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI HOCHEDLINGER, KONRAD · 2020 to 2024
$2.2M
NCI NIH HHS U54 CA193461NIAMS NIH HHS R01 AR076394NIAMS NIH HHS R01 AR077695NIA NIH HHS DP1 AG063419NIA NIH HHS R01 AG048917NICHD NIH HHS R01 HD058013NIDDK NIH HHS P30 DK040561NIDDK NIH HHS T32 DK007260NIGMS NIH HHS P01 GM099134
6 · The paper itself

Abstract

The generation of myotubes from fibroblasts upon forced MyoD expression is a classic example of transcription factor-induced reprogramming. We recently discovered that additional modulation of signaling pathways with small molecules facilitates reprogramming to more primitive induced myogenic progenitor cells (iMPCs). Here, we dissected the transcriptional and epigenetic dynamics of mouse fibroblasts undergoing reprogramming to either myotubes or iMPCs using a MyoD-inducible transgenic model. Induction of MyoD in fibroblasts combined with small molecules generated Pax7

Indexed as

Muscle DevelopmentMyoD ProteinAnimalsCell DifferentiationMiceMuscle Fibers, SkeletalMuscle, SkeletalMyoblastsStem CellsMyoD ProteindedifferentiationDNA methylationepigenetic reprogramminginduced myogenic progenitor cells (iMPCs)MyoDsatellite cellstransdifferentiation

Identifiers

PMID34413137
PMCPMC8415322
OpenAlexW3194830864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.